The retrospective analysis compared 76 phase 1b participants with 360 historical registry patients selected using similar age, diagnosis, conditioning and donor-match criteria.
The C$1 million grant will support development of an oral medicine designed to restore blood-forming stem cells and rebuild the immune system.
In mice with collagen-induced arthritis, several ERNA-201 candidates lowered disease severity versus untreated controls, while the company shifts near-term spending to ERNA-101’s planned ovarian cancer trial filing.
The project will test whether GenomeFrontier’s virus-free process, including electroporation-based transfection, can be adapted to Cellares’ automated system to support U.S. clinical manufacturing.
Up to 40 patients with relapsed or refractory multiple myeloma may enroll to test an approach designed to generate engineered T cells inside the body.
The investigators will evaluate a dual-target CAR T-cell therapy designed to attack B7-H3 and IL-8 in adults and children with advanced solid tumors.
The Australian CDMO will manufacture A-SEEDS' therapy for the upcoming trial down under.
Following Phase 3, TREGZI, known as Orca-T, had higher graft-versus-host disease-free survival at one year in patients receiving conventional blood stem cell transplants.
Verismo is ramping up its 2 Phase 1s targeting solid tumors and B-Cell non-Hodgkin lymphomas, selecting Cryoport for its cold chain.
Cell and gene therapies are advancing quickly, but the systems needed to deliver them at scale are still lagging behind. Terumo’s new Ecosystem Blueprint aims to bridge that gap in Asia-Pacific by integrating workflows, equipment, and training into a coordinated model to move from isolated…
Cartherics is developing multiple immune cell therapies for women's health, including its lead candidate, CTH-401, a CAR-NK therapy targeting ovarian cancer.
The company is evaluating whether Cellular Origins’ Constellation automation platform can be used in selected Immatics manufacturing steps to improve consistency, efficiency, and scalability for next-generation cancer cell therapies.
A phase 2 trial found that adding a lab-expanded stem cell product made from multiple pooled cord blood donors to a single cord blood transplant may broaden access to transplants for leukemia and myelodysplastic syndrome patients by speeding early immune recovery while avoiding severe transplant…
HexemBio plans to advance its platform designed to rejuvenate aging blood stem cells, with an initial focus on improving bone marrow transplant outcomes in blood cancers.
This is part of J&J's $55B investment in US manufacturing over the next few years.
The new platforms aim to streamline large-scale production of iPSC-derived cell therapies for new indications.
Eight California research centers receive funding to expand cell and gene therapy manufacturing.
The new grants will support diverse early-stage research projects, aiming to advance regenerative medicine tools and future therapies.
Calidi’s CLD-201, a novel stem cell-based oncolytic virus therapy, moves forward.
Researchers are exploring whether stem cell-derived extracellular vesicles could offer safer, targeted therapies for respiratory diseases, but technical hurdles remain.
It's interesting to consider, much like with umbilical cords, how often are we incinerating life-saving stem cells?
The company plans on moving to Phase 2 later this year, hopefully supporting a BLA in the near future.
The new facility at CEPM positions Cell BioEngines to accelerate research and forge partnerships advancing innovative cell therapies.